CompareIsomorphic LabsvsRecursion

Isomorphic Labs is a DeepMind spinout building AI models for drug design, including protein structure prediction and molecule generation for pharma partners. The product is positioned around R&D acceleration and computational biology rather than guaranteed clinical outcomes, and engagement typically happens through pharma partnerships rather than self-serve subscription buying. Buyers should weigh data access requirements, expected timelines to validated leads, and the cost structure across collaborations before committing to a long discovery program today.

For large pharma partners and biologics programs, Isomorphic Labs is worth a serious look thanks to frontier ai models for biologics design. The honest trade-off is that not a self-serve buyer product today. Pricing is sales-led and scoped per buyer rather than posted publicly. Buyers should still verify EHR or workflow fit, scope, and support before committing.

Recursion is an AI drug discovery company that uses cellular imaging, automation, and machine learning to identify and validate new drug candidates. The product is positioned around R&D acceleration and computational biology rather than guaranteed clinical outcomes, and engagement typically happens through pharma partnerships rather than self-serve subscription buying. Buyers should weigh data access requirements, expected timelines to validated leads, and the cost structure across collaborations before committing to a long discovery program today.

The clearest fit for Recursion is pharma collaborators and internal pipeline programs, with the platform leaning into phenomics platform with multimodal data. Limitations are real: direct buyer access is limited to partnerships. Pricing is sales-led and scoped per buyer rather than posted publicly. Buyers should confirm validation depth, support coverage, and rollout plan before signing.